Compare Abeona Therapeutics Inc (ABEO) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Consumer Discretionary Select Sector SPDR Fund trades at $115.12. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Consumer Discretionary Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| ABEO | XLY | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $124.52 |
52-Week Low | $4.17 | $105.64 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
XLY trades at $118.01, up 0.77% today, with a bullish technical signal from moving averages and support at $117. Analyst consensus is unanimously positive with 100% buy ratings, though key valuation metrics remain unavailable. Recent news highlights consumer discretionary sector strength during holiday spending periods.
The ETF's outlook remains favorable given strong technical momentum and positive analyst sentiment, though investors should monitor consumer spending trends and inflation impacts. Key risks include macroeconomic pressures on discretionary spending and sector competition from alternative funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
